HopeStage
Back to all studies
CompletedNCT05859698

Patient and clinician outcomes with valbenazine treatment

About this titleRead the official source — NCT05859698
Medication studyAges 18+United StatesSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: from 18 years.

Listed locations
Bryant and 17 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: May 9, 2023
Recruitment status
Completed
Enrollment listed in the registry
59
Sponsor
Neurocrine Biosciences
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
Over 18 Years
Official registry ID
NCT05859698
Official title
Show the full official title

A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Bryant · Anaheim · Orange

15 more locations
  • Torrance
  • Bonita Springs
  • Miami
  • Miami Lakes
  • Okeechobee
  • Tampa
  • Atlanta
  • Augusta
  • Marietta
  • Lincoln
  • Beechwood
  • Oklahoma City
  • DeSoto
  • El Paso
  • Houston

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Neurocrine Biosciences, a biotech company.

Did this study involve medication?

Yes. The study involved medication, including Valbenazine.

Who was this study for?

Listed age limits: from 18 years.

Want to explore more studies?

Explore studies